Blue Jet Healthcare Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹2,346.68 Million
    • QoQ Change: +21.96%
    • YoY Change: -31.08%
  • Previous Quarter (Q3 FY26): ₹1,924.14 Million
  • Previous Year (Q4 FY25): ₹3,404.45 Million
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹643.44 Million
    • QoQ Change: +60.20%
    • YoY Change: -41.56%
  • Previous Quarter (Q3 FY26): ₹401.66 Million
  • Previous Year (Q4 FY25): ₹1,100.95 Million
• QoQ Performance:
  • Revenue Trend: Revenue recovered strongly quarter-on-quarter with healthy operational improvement.
    
  • Profit Trend: Profit growth significantly outpaced revenue growth, indicating margin normalization and improved efficiency.

Margin Analysis

Drivers:

• Better absorption of fixed operating costs during Q4.
• Lower finance costs supported profitability.
• Improved inventory movement aided gross margins.
• Employee expense remained stable sequentially.
• Depreciation increased due to ongoing capacity additions.

Insight:

• Sequential margin recovery indicates operational stabilization despite softer annual performance.

Segment insight

Business Summary:

Blue Jet Healthcare operates in specialized pharmaceutical and healthcare intermediate manufacturing with export-oriented operations.

Key Characteristics:

• Focus on niche pharma intermediates.
• Export-driven business model.
• High-value chemistry capabilities.
• Strong manufacturing-led operating structure.

Earning quality check

Key Drivers:

• Net operating cash flow surged to ₹3,341.46 million from ₹457.65 million YoY.
• Working capital movement improved substantially.
• Trade receivables normalized during FY26.
• Strong cash generation despite lower annual profits.
• Limited debt burden maintained balance sheet strength.

Interpretations:

• Cash flow quality improved materially in FY26, indicating stronger operational conversion and better working capital management.

balance sheet Analysis

• Total Assets FY26: ₹16,411.58 million
• Total Assets FY25: ₹14,175.31 million
• Total Equity FY26: ₹13,599.12 million
• Total Equity FY25: ₹11,331.11 million
• Total Liabilities FY26: ₹2,812.46 million
• Total Liabilities FY25: ₹2,844.20 million

Key Balance Sheet Observations:

• Capital work-in-progress increased sharply to ₹3,013.76 million from ₹888.84 million.
• Cash and cash equivalents improved to ₹608.57 million.
• Current assets declined due to inventory reduction.
• Equity strengthened through retained earnings accumulation.

Insight:

• The balance sheet remains healthy with strong equity growth and ongoing expansion investments positioning the company for future capacity enhancement.

key risks

• Revenue concentration risks in specialized products.
• Export market dependency.
• Margin volatility due to product mix changes.
• Capex execution risks from ongoing expansion.
• Currency fluctuation exposure.

management strategy signals

Focus Area:

• Expansion of manufacturing capacities.
• Strengthening specialty product portfolio.
• Improving operational efficiency.
• Scaling export opportunities.
• Investment in high-value pharma intermediates.

Financial metrics table

Quarterly Performance Context